

NashvillePost

AREA STOCKS

Cumberland Pharmaceuticals stock soars once more

Company sees shares skyrocket 28.4 percent in value after approval of injection drug for use in China

WILLIAM WILLIAMS FEB 19, 2025

Cumberland Pharmaceuticals saw its shares surge Wednesday after news that the company's Vibativ injection has been approved for use in China.

At the end of the trading session, the stock (ticker: [CPIX](#)) was valued at \$6.19 per share, up 28.42 percent (the equivalent increase of \$1.37).

Approximately 1.48 million Cumberland Pharmaceuticals shares changed ownership hands for the day, according to Yahoo Finance. On average and for the past 30 days, about 3.48 million shares have traded daily.

On Tuesday Cumberland Pharmaceuticals and fellow specialty pharmaceutical company SciClone Pharmaceuticals Limited announced the National Medical Products Administration has approved the Vibativ injection for the Chinese market. Vibativ is an antibiotic used to treat pneumonia and serious skin infections.

The significant stock uptick Wednesday comes only 15 days after Cumberland Pharmaceuticals finished the Feb. 4 trading day up 76 percent on heavy volume following positive results from a trial for heart disease drug Ifetroban (read [here](#)). The stock of the Nashville-based drug company concluded that session priced at \$3.76, up \$1.63 per share (the equivalent increase of 76.5 percent). Approximately 18 million Cumberland Pharmaceuticals shares traded that day.

Prior to Wednesday, Cumberland Pharmaceuticals stock was last valued at more than \$6 per share in May 2019.